Scholarlink

Purpose of the Review <p>Breast cancers predominantly express estrogen receptor (ER), and therapies targeting the ER pathway have significantly improved patient survival over decades. Approvals of additional targeted agents such as CDK4/6 inhibitors, PI3K/AKT/mTOR inhibitors, and HER2-targeted antibodies have further enhanced outcomes. Yet, ongoing efforts are crucial to identify new drug targets and develop combination therapies to address evolving tumor adaptations in these patients.</p> Recent Findings <p>In the past decade, disrupted epigenetic regulation has emerged as a critical factor in various cancers, including breast cancer. Chromatin modifiers and transcription factors play pivotal roles in disease development and treatment outcomes. Integrating novel epigenetic-based therapies with existing targeted treatments presents a promising strategy against resistance.</p> Summary <p>This review examines cutting-edge advancements in endocrine therapy and PI3K/AKT inhibitors in ER + breast cancer. Additionally, it explores pivotal chromatin-based mechanisms influencing breast cancer progression and treatment response. Lastly, it highlights the potential of targeting epigenetic regulators as a promising approach to combat therapy resistance in breast cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Epigenetic Therapy in Hormone Positive Breast Cancer: The Role of PIK3CA

  • 期刊论文

  • 发表日期：

    2025年1月31日

查看全文
  • Ryan Blawski,
  • Eneda Toska

摘要

Purpose of the Review

Breast cancers predominantly express estrogen receptor (ER), and therapies targeting the ER pathway have significantly improved patient survival over decades. Approvals of additional targeted agents such as CDK4/6 inhibitors, PI3K/AKT/mTOR inhibitors, and HER2-targeted antibodies have further enhanced outcomes. Yet, ongoing efforts are crucial to identify new drug targets and develop combination therapies to address evolving tumor adaptations in these patients.

Recent Findings

In the past decade, disrupted epigenetic regulation has emerged as a critical factor in various cancers, including breast cancer. Chromatin modifiers and transcription factors play pivotal roles in disease development and treatment outcomes. Integrating novel epigenetic-based therapies with existing targeted treatments presents a promising strategy against resistance.

Summary

This review examines cutting-edge advancements in endocrine therapy and PI3K/AKT inhibitors in ER + breast cancer. Additionally, it explores pivotal chromatin-based mechanisms influencing breast cancer progression and treatment response. Lastly, it highlights the potential of targeting epigenetic regulators as a promising approach to combat therapy resistance in breast cancer.